Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Rishi Wadhera

General Cardiology · BIDMC

View

Dr. Robert Harrington

General Cardiology · WCM

View

Dr. Mike Gaziano

General Cardiology · BWH

View

Dr. Tyler Gluckman

General Cardiology · Providence

View

Dr. Cayla Pichan

General Cardiology · UT Southwestern

View

Dr. Sanjiv Kaul

General Cardiology · OHSU

View

Dr. Emily Lau

General Cardiology · MGH

View

Dr. Sarah Ashley

General Cardiology · Emory University Hospital

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

    Jun 11, 2026DOI: 10.1056/nejmc2604760CorrespondenceNEJM

    Summary

    To the Editor: The Comparison of Bleeding Risk between Rivaroxaban and Apixaban (COBRRA) trial by Castellucci et al. (March 12/19 issue) established the superiority of apixaban over rivaroxaban with regard to bleeding risk among patients with acute venous thromboembolism (VTE). However, a critical confounding variable — the difference in medication adherence — warrants discussion. The article mentions that “complete adherence” was reported by 65.7% of the patients in the apixaban group and by 75.1% of those in the rivaroxaban group. This gap of 9.4 percentage points is likely to be attributable to the twice-daily regimen of apixaban as compared with . . .
    JEDr. Johann Alexandre Edjimbi

    Dr. Johann Alexandre Edjimbi

    Cardiology · General Non-Invasive Cardiology
    Sinai Hospital of Baltimore
    johannalexandre